Kinetics Medical Fund

2 / 5 Stars
2 2 5 1 3
Zacks Investment Research
1 (Strong Buy)
Standard & Poor's
2 / 5 Stars
B+ (Buy)

#23 in Health

U.S. News evaluated 34 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.

See all Kinetics funds

See full Health rankings

See more fund rankings


The fund has returned 47.81 percent over the past year, 22.25 percent over the past three years, 22.12 percent over the past five years, and 9.91 percent over the past decade.

Trailing Returns Updated 02.28.2014
Year to date 9.4%
1 Year 47.8%
3 Years (Annualized) 22.3%
5 Years (Annualized) 22.1%
10 Years (Annualized) 9.9%

See more KRXAX performance


The investment seeks long-term growth of capital. The fund normally invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, generally, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.


Fees are Low compared to funds in the same category.
Kinetics Medical Fund has an expense ratio of 1.64 percent.

See more KRXAX fees


Risk is Above Average compared to funds in the same category according to Morningstar.

See more KRXAX risk